214 related articles for article (PubMed ID: 28631628)
1. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions.
Golu I; Vlad MM; Dema A; Moleriu LC; Tudor A; Iacob M; Popa O; Cornianu M
Indian J Pathol Microbiol; 2017; 60(2):161-166. PubMed ID: 28631628
[TBL] [Abstract][Full Text] [Related]
2. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
6. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
7. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
8. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma.
Shahebrahimi K; Madani SH; Fazaeli AR; Khazaei S; Kanani M; Keshavarz A
Indian J Pathol Microbiol; 2013; 56(1):2-5. PubMed ID: 23924549
[TBL] [Abstract][Full Text] [Related]
9. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
12. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
13. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules.
Abd El Atti RM; Shash LS
J Egypt Natl Canc Inst; 2012 Dec; 24(4):175-84. PubMed ID: 23159288
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
15. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP.
Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M
Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
17. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
[TBL] [Abstract][Full Text] [Related]
18. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
El Demellawy D; Nasr A; Alowami S
Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of the Follicular Variant of Papillary Thyroid Carcinoma From Classic Papillary Thyroid Carcinoma: An Ultrasound Analysis and Complement to Fine-Needle Aspiration Cytology.
Ng SC; Kuo SF; Hua CC; Huang BY; Chiang KC; Chu YY; Hsueh C; Lin JD
J Ultrasound Med; 2018 Mar; 37(3):667-674. PubMed ID: 28880405
[TBL] [Abstract][Full Text] [Related]
20. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19.
Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N
Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]